Jilin Provincial Cancer Hospital (Changchun Cancer Hospital)

Changchun, Jilin 130000

0 studies enrolling now · 2 studies all time

What they study most

ALK+ Advanced NSCLC, ALK-positive Advanced NSCLC

Studies at this site

• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer — Completed
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed